To the Editor We were interested by a recently published article in JAMA Oncology.1 The meta-analysis included 43 trials containing 8 randomized clinical trials with 5431 patients to compare the efficacy of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy. They found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. This is a promising result for neoadjuvant chemoimmunotherapy, an emerging oncology treatment approach. However, we had some questions about the meta-analysis methods.

Meta-Analysis; Chemoimmunotherapy; Non–Small Cell Lung Cancer